What is the clinical evidence from this study?

Study design: Other. Population: Arterial thrombosis. Intervention: DTCC-RGDV vs. Normal saline (NS). Primary outcome: Arterial thrombus weight (p=<0.01).

What question did this study set out to answer?

The central aim is to identify a compound capable of targeting arterial thrombi and releasing anti-thrombotic agents.

April 23, 2026Open Access

DTCC–RGDV: a nano-scaled conjugate capable of targeting arterial thrombi and releasing anti-thrombotic pharmacophore DTCC

Q: What are the key findings of this study?

Oral administration of 0.01 mmol/kg DTCC-RGDV significantly reduced arterial thrombus weight in rats compared to normal saline (p<0.01).

Q: What question did this study set out to answer?

The central aim is to identify a compound capable of targeting arterial thrombi and releasing anti-thrombotic agents.

Key Result

Oral administration of 0.01 mmol/kg DTCC-RGDV significantly reduced arterial thrombus weight in rats compared to normal saline (p<0.01).

Key Points

The central aim is to identify a compound capable of targeting arterial thrombi and releasing anti-thrombotic agents.
Conducted docking experiments with P-selectin and GPIIb/IIIa.
Utilized virtual screening techniques to evaluate potential lead compounds.
(3S)-DTCC was identified as a promising lead compound for targeting thrombi.
Docking studies suggest effective interaction with intended targets.

Structured PICO

Population

Male ICR rats (230-270 g) and in vitro models (P-selectin, GPIIb/IIIa, rat erythrocytes, leukocytes, and platelets)

Intervention

DTCC (1 mmol/kg oral) and its nano-scaled conjugate DTCC-RGDV

Comparator

Normal saline (blank control) and RGDV (20 mmol/kg oral)

Outcome

Arterial thrombus weightsurrogate

DTCC and its nano-scaled conjugate DTCC-RGDV demonstrate significant anti-arterial thrombotic activity in a rat model by targeting P-selectin and GPIIb/IIIa without causing liver or kidney injury.

Main Result

p-value: p=<0.01

Limitations

Preclinical animal model study; results may not directly translate to humans
Exact numerical values for thrombus weights are not provided in the text, only statistical significance

Abstract

Through P-selectin and GPIIb/IIIa docking experiments, virtual screening identified (3 S )-1-[(5,5-dimethyl-3,4-dioxan-1-yl)-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid (DTCC) as a potential lead compound.

Bookmark

View Full Paper

Bookmark

View Full Paper

Cite This Study

Zhang et al. (Thu,) conducted a other in Arterial thrombosis. DTCC-RGDV vs. Normal saline (NS) was evaluated on Arterial thrombus weight (p=<0.01). Oral administration of 0.01 mmol/kg DTCC-RGDV significantly reduced arterial thrombus weight in rats compared to normal saline (p<0.01).

synapsesocial.com/papers/69e9baeb85696592c86ecd45 https://doi.org/https://doi.org/10.1039/d6ma00386a